Please assess the completion status of the following clinical trial:

Trial Title: HBV Vaccine in Renal Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients recruited have to be aged ≥ 21 years, with history of chronic renal failure and on renal replacement therapy (continuous ambulatory peritoneal dialysis or hemodialysis).~* All patients have to give written informed consent and will have up to 1 week period to decide.~* Subjects must be available to complete the study and comply with study procedures.~* Patients are willing to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.~* All recruited subjects have to be HBsAg, anti-HBs and anti-HIV negative before recruitment.~Exclusion Criteria:~* Inability to comprehend and to follow all required study procedures~* History or any illness that might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.~* Have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination.~* Have a known allergy to components of the Study Vaccines.~* Have a positive urine or serum pregnancy test within 24 hours prior to vaccination, or women who are breastfeeding.~* Have an active neoplastic disease or a history of any hematologic malignancy.~* Have known chronic active hepatitis B and hepatitis C (HBsAg+ve and anti-HCV+ve).~* Have known active human immunodeficiency virus (HIV).~* Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study.~* Unwilling to refuse participation in another clinical study through the end of this study.~* Axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended study vaccination.~* Have a history of alcohol or drug abuse in the last 5 years.~* Have any condition that the investigator believes may interfere with successful completion of the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intradermal HBVv with imiquimod (Type: EXPERIMENTAL): Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
- Intradermal HBVv with aqueous cream (Type: ACTIVE_COMPARATOR): Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
- Intramuscular HBVv with aqueous cream (Type: ACTIVE_COMPARATOR): Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).